{"preliminary_commentary":{"by_channel":{"x_thread":13},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03469960\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab","ipilimumab"]],"indication":"PD-L1-positive stage IV non-small cell lung cancer","name":"DICIPLE","nct_id":"NCT03469960","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=diciple-nct03469960. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DICIPLE","arms":[{"description":"6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended","label":"Arm A : standard treatment","type":"ACTIVE_COMPARATOR"},{"description":"6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended","label":"Arm B : experimental arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-10-15","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer Metastatic"],"enrollment":{"count":265,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ipilimumab","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"}],"last_update":"2025-11-18","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","official_title":"A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction Treatment","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-11-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS1)","timeFrame":"24 months after randomization of the last subject"}],"references":[],"start_date":{"date":"2018-05-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr","url":"https://clinicaltrials.gov/study/NCT03469960"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/diciple-nct03469960"}